This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma

This study has been completed.
Information provided by:
Neovii Biotech Identifier:
First received: July 14, 2006
Last updated: October 25, 2007
Last verified: June 2007
Investigation of the outcome of an adjuvant treatment with catumaxomab as compared to surgery alone in patients after curative resection of a gastric adenocarcinoma in order to gain more detailed information primary on safety, tolerability and feasibility and secondary on relevant efficacy parameters.

Condition Intervention Phase
Gastric Cancer Gastric Adenocarcinoma Drug: catumaxomab Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Open-Label and Randomized Phase II Study to Evaluate Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients After Curative Resection of a Confirmed Gastric Adenocarcinoma Compared With Surgery Alone

Resource links provided by NLM:

Further study details as provided by Neovii Biotech:

Primary Outcome Measures:
  • safety and efficacy data

Estimated Enrollment: 40
Study Start Date: July 2006
Study Completion Date: September 2007
Detailed Description:

A controlled, randomized, open-label, multi-center, parallel-group, Phase II study to generate valid hypotheses on safety and efficacy issues in patients with a primary confirmed diagnosis of gastric adenocarcinoma and a high risk of disseminated tumor cells due to serosal infiltration after curative gastrectomy. Eligible patients will be centrally randomized by IVRS during operation to one of the two study groups in an 1:1 ratio: surgery plus catumaxomab or surgery alone.

Treatment with catumaxomab will consist of an initial dose of 10 µg given intraoperatively as an intraperitoneal bolus on day 0 and of four following ascending doses (10-20-50-150 µg) which will be administered as an i.p.-infusion via a provided indwelling catheter on the days 7, 10, 13 and 16, respectively.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed and dated informed consent
  • Patient has a primary diagnosis of a histologically confirmed gastric adenocarcinoma (including GE junction Siewert-Type 2 or 3)
  • Intended curative gastrectomy (`en-bloc´-R0-resection considering the standard D2-scheme)
  • Serosal infiltration (T3/T4, N+/-, M0) confirmed by immediate section with histopathologic assessment during surgery
  • Karnofsky index >= 70
  • Negative pregnancy blood test at screening in women with childbearing potential

Exclusion Criteria:

  • Presence of distant metastases
  • Macroscopic and microscopic residual tumor present after surgery
  • State after pancreas resection or thoracotomy
  • Exposure to prior cancer therapy or planned adjuvant chemo-or radiotherapy of the current gastric cancer
  • Previous treatment with non-humanized mouse or rat monoclonal antibodies
  • Known/suspected hypersensitivity to catumaxomab or similar antibodies
  • Any cancer disease or any cancer treatments within the last 5 years
  • Presence of constant immunosuppressive therapy
  • Inadequate renal function (creatinine > 1.5 x ULN)
  • Inadequate hepatic function (AST or ALT > 2.5 x ULN or bilirubin >= 1.5 x ULN)
  • Platelets < 75000 cells/mm³; absolute neutrophil count < 1500 cells/mm³
  • Patient had a bowel obstruction within the last 30 days
  • Pregnant or nursing woman, or woman of childbearing potential who is not using an effective contraceptive method during the study and at least contraceptives, intrauterine devices, double-barrier method, contraceptive patch, male partner sterilization or condoms)
  • Presence of any acute or chronic systemic infection
  • Any further condition which according to the investigator results in an undue risk to the patient during participating in the present study
  • Patient is an employee of any involved study investigator or any involved institution including the study sponsor
  • Parallel participation in another clinical trial or previous participation in this study
  • Treatment with another investigational product during this study or during the last 30 days prior to study start
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00352833

Hospital of Cologne-Merheim, Surgical Department
Cologne, Germany, 51109
Sponsors and Collaborators
Neovii Biotech
Principal Investigator: Marcus Heiss, Prof. Dr. Cologne, Germany
  More Information

Publications: Identifier: NCT00352833     History of Changes
Other Study ID Numbers: IP-REM-GC-02
Study First Received: July 14, 2006
Last Updated: October 25, 2007

Keywords provided by Neovii Biotech:
gastric cancer
investigational drug
adjuvant therapy
EpCAM-positive tumor

Additional relevant MeSH terms:
Stomach Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antibodies, Bispecific
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017